Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12569507 | CAR T-cells for the treatment of bone metastatic cancer | 🖼🧊📄§ | 2026-03-10 | 2041-02-05 | 0 | 31 |
| 12564646 | Treatment of age-related cognitive decline using genetically modified viral vectors | 🖼🧊📄§ | 2026-03-03 | 2042-06-15 | 0 | 31 |
| 12565648 | MicroRNA-mediated methods for rejuvenating CNS glial populations | 🖼🧊📄§ | 2026-03-03 | 2042-10-19 | 0 | 31 |
| 12564642 | CEACAM5 antibody-drug conjugate formulation | 🖼🧊📄§ | 2026-03-03 | 2041-11-09 | 0 | 31 |
| 12565539 | Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression | 🖼🧊📄§ | 2026-03-03 | 2043-11-21 | 0 | 31 |
| 12565537 | Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation | 🖼🧊📄§ | 2026-03-03 | 2040-06-18 | 0 | 31 |
| 12564575 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | 🖼🧊📄§ | 2026-03-03 | 2042-04-21 | 0 | 31 |
| 12565530 | Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody | 🖼🧊📄§ | 2026-03-03 | 2043-02-09 | 0 | 31 |
| 12564648 | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors | 🖼🧊📄§ | 2026-03-03 | 2045-04-24 | 0 | 31 |
| 12565653 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-20 | 0 | 31 |
| 12564202 | Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient | 🖼🧊📄§ | 2026-03-03 | 2040-09-25 | 0 | 31 |
| 12564593 | Topical formulation for a JAK inhibitor | 🖼🧊📄§ | 2026-03-03 | 2045-07-18 | 0 | 31 |
| 12564568 | PKC pathway in Parkinson's Disease | 🖼🧊📄§ | 2026-03-03 | 2039-04-05 | 0 | 31 |
| 12564643 | Polymeric nanovaccines and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2039-12-27 | 0 | 31 |
| 12564590 | Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2041-04-07 | 0 | 31 |
| 12564597 | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | 🖼🧊📄§ | 2026-03-03 | 2041-03-04 | 0 | 31 |
| 12565649 | Methods of rescuing stop codons via genetic reassignment with ACE-tRNA | 🖼🧊📄§ | 2026-03-03 | 2043-04-21 | 0 | 31 |
| 12564586 | Kappa opiod receptor antagonists for treating pain-related sleep disorders | 🖼🧊📄§ | 2026-03-03 | 2041-04-09 | 0 | 31 |
| 12564600 | System for enhancing therapeutic compliance of the anti-cancer compound E7766 | 🖼🧊📄§ | 2026-03-03 | 2040-07-01 | 0 | 31 |
| 12564613 | Strains having effects of preventing or treating cancers | 🖼🧊📄§ | 2026-03-03 | 2039-05-08 | 0 | 31 |
| 12564607 | Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same | 🖼🧊📄§ | 2026-03-03 | 2040-06-12 | 0 | 31 |
| 12564638 | EGFR protein degradant and anti-tumor application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-08-05 | 0 | 31 |
| 12565485 | Solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((s)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one | 🖼🧊📄§ | 2026-03-03 | 2043-02-03 | 0 | 31 |
| 12564589 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | 🖼🧊📄§ | 2026-03-03 | 2045-03-18 | 0 | 31 |
| 12565651 | Oligonucleotides comprising segmented gap structures | 🖼🧊📄§ | 2026-03-03 | 2044-07-10 | 0 | 31 |
| 12565531 | Bispecific fusion protein for tumor treatment | 🖼🧊📄§ | 2026-03-03 | 2040-12-03 | 0 | 31 |
| 12564563 | Composition and methods for treating pathogenic infections on wounds | 🖼🧊📄§ | 2026-03-03 | 2040-12-22 | 0 | 31 |
| 12565660 | Immunomodulating transgenic plants and related methods | 🖼🧊📄§ | 2026-03-03 | 2044-01-24 | 0 | 31 |
| 12564617 | Methods for modulating macrophage activity | 🖼🧊📄§ | 2026-03-03 | 2041-09-17 | 0 | 31 |
| 12564628 | Epstein-BARR virus nucleic acid constructs and vaccines made therefrom, and methods of using same | 🖼🧊📄§ | 2026-03-03 | 2042-06-22 | 0 | 31 |
| 12565527 | IL13 and IL31 bispecific polypeptides and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2045-09-02 | 0 | 31 |
| 12564609 | Hematopoietic stem cell engraftment with a combination of agents | 🖼🧊📄§ | 2026-03-03 | 2041-10-14 | 0 | 31 |
| 12564580 | Mitochondria-targeted isoketal/isolevuglandin scavengers and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2041-01-27 | 0 | 31 |
| 12564581 | Pyrazole pharmaceutical composition | 🖼🧊📄§ | 2026-03-03 | 2040-12-18 | 0 | 31 |
| 12564611 | Pancreatic endocrine progenitor cells and use thereof | 🖼🧊📄§ | 2026-03-03 | 2040-09-17 | 0 | 31 |
| 12564564 | Composition comprising tyrosol and amino acids and its application in enhancing athletic performance and combating fatigue | 🖼🧊📄§ | 2026-03-03 | 2044-11-24 | 0 | 31 |
| 12564620 | Treatment of gulf war illness | 🖼🧊📄§ | 2026-03-03 | 2042-09-15 | 0 | 31 |
| 12564567 | Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus | 🖼🧊📄§ | 2026-03-03 | 2043-11-27 | 0 | 31 |
| 12564641 | Eribulin antibody-drug conjugates and methods of use | 🖼🧊📄§ | 2026-03-03 | 2042-12-23 | 0 | 31 |
| 12564566 | Uses of long-chain polyunsaturated fatty acids | 🖼🧊📄§ | 2026-03-03 | 2040-08-07 | 0 | 31 |
| 12564610 | Human periventricular endothelial cell therapy for neuropsychiatric disorders | 🖼🧊📄§ | 2026-03-03 | 2040-10-19 | 0 | 31 |
| 12564588 | HECT E3 ubiquitin liagase inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-03 | 2042-01-21 | 0 | 31 |
| 12564625 | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-Δ5nsP3 | 🖼🧊📄§ | 2026-03-03 | 2044-05-06 | 0 | 31 |
| 12564591 | HCK as a therapeutic target in MYD88 mutated diseases | 🖼🧊📄§ | 2026-03-03 | 2040-10-07 | 0 | 31 |
| 12564571 | Compositions and methods for the treatment of equine protozoal myeloencephalitis | 🖼🧊📄§ | 2026-03-03 | 2039-02-20 | 0 | 31 |
| 12565523 | Structure-guided engineering of peptide-based NLRP3 inflammasome inhibitors for myelodysplastic syndromes (MDS) | 🖼🧊📄§ | 2026-03-03 | 2040-05-01 | 0 | 31 |
| 12564572 | Topical ocular delivery of cromakalim | 🖼🧊📄§ | 2026-03-03 | 2044-10-04 | 0 | 31 |
| 12565654 | Extracellular vesicle secretion reducing agent for reducing extracellular vesicle secretion, and use of the same | 🖼🧊📄§ | 2026-03-03 | 2041-04-07 | 0 | 31 |
| 12565522 | Micropeptide HMMW and application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-11-03 | 0 | 31 |
| 12564624 | Ostrich antibody for bacterial infectious diseases | 🖼🧊📄§ | 2026-03-03 | 2044-04-11 | 0 | 31 |